NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and
commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen
Biotech, will present details around its NK cell therapy in neurodegenerative disease, review its preclinical data in Parkinson’s disease, and highlight clinical safety and efficacy data from the
Company’s recently completed Phase 1 clinical trial of SNK01, autologous natural killer cell therapy, in Alzheimer’s disease at the 12th Annual Alzheimer’s & Parkinson’s Drug
Development Summit to be held in Boston, MA, from April 23–25, 2024.
Presentation Details: | |
Title: | Evaluating Adoptive Cellular Immunotherapy for Neurodegeneration with Autologous SNK01 |
Conference Track: | Translational -- Harnessing Cell Therapy & Senescence to Reduce Alzheimer's Pathology in Preclinical Research |
Date and Time: | Thursday, April 25, 2024, 2:00 pm ET |
Dr. Song’s presentation will detail how enhanced natural killer cells can maximize the body’s ability to destroy diseased and abnormal cells and provide a review of NK cell therapy as an alternative treatment modality to resolve neurodegeneration by harnessing the body’s natural immune system, including a discussion on the scientific rationale behind the use of NK cell therapy for the treatment of Parkinson’s disease. Dr. Song will also present clinical safety and efficacy data from the Company’s recently completed Phase 1 clinical trial evaluating autologous SNK01 NK cell therapy in patients with Alzheimer’s disease (NCT04678453).
Lesen Sie auch
A copy of the presentation will be available on the Scientific Publications page of the Company’s website at https://nkgenbiotech.com/ once the presentation has concluded. Previously disclosed Phase 1 data on the positive effects of SNK01 on amyloid, tau and neuroinflammation biomarkers, which may not be included in this conference presentation, can also be found on the Scientific Publications page.